Clinical variables improve efficacy of ECG scores to diagnose the left ventricular hypertrophy in general population

Abstract   Left ventricular hypertrophy (LVH) is an important risk factor of various cardiovascular (CV) diseases and sudden death. Electrocardiography (ECG) is commonly used to detect LVH, but it has poor sensitivity, especially in high cardiovascular risk patients. Although echocardiography (ECHO)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2020-11, Vol.41 (Supplement_2)
Hauptverfasser: Jamiolkowski, J, Chlabicz, M, Paniczko, M, Sowa, P, Szpakowicz, M, Lapinska, M, Jurczuk, N, Drobek, N.A, Sawicka, E, Raczkowski, A, Kaminski, K.A
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_2
container_start_page
container_title European heart journal
container_volume 41
creator Jamiolkowski, J
Chlabicz, M
Paniczko, M
Sowa, P
Szpakowicz, M
Lapinska, M
Jurczuk, N
Drobek, N.A
Sawicka, E
Raczkowski, A
Kaminski, K.A
description Abstract   Left ventricular hypertrophy (LVH) is an important risk factor of various cardiovascular (CV) diseases and sudden death. Electrocardiography (ECG) is commonly used to detect LVH, but it has poor sensitivity, especially in high cardiovascular risk patients. Although echocardiography (ECHO) is a better, it is less available, and more expensive. Aim: To improve ECG scores to diagnose LVH in a general population. Methods The study was conducted in 2017–2019 in a representative sample of area residents. 717 volunteers randomly chosen from the local population were examined. Due to incomplete data, QRS complex duration ≥120ms, fascicular blocks, bundle branch blocks, paced rhythm, 216 people were excluded. Physical examination, ECG, ECHO and laboratory assessment were performed. In ECG LVH defined as >28mm for men, >20mm for women using Cornell index; >17mm for both sexes using Lewis index. In ECHO LV mass was calculated using the Devereux Formula and indexed by body surface area (left ventricular mass index – LVMI). The LVH was defined as LVMI ≥115 g/m2 for man and ≥95 g/m2 for women. Cardiovascular risk was calculated based on the ESC SCORE and additional risk categories published in the latest ESC guidelines. We analyzed 4 models to predict the probability of LVH at ECHO: Model 1: Cornell index; Model 2: Lewis index; Model 3: Cornel index + clinical parameters (age, sex, BMI, office BPs, QRS time, hs-TnT, and HbA1c); Model 4: Lewis index + clinical parameters (age, sex, BMI, office BPs, QRS time, hs-TnT, and HbA1c). Associations between LVH and clinical and biochemical variables were earlier analyzed using multiple linear regression models, these parameters were independently associated with LVH. Results A total of 501 patients were included. The average age of patients was 49.0±15.35 years, and 203 probants (40.5%) were male. We developed a novel score to assess the probability of LVH at ECHO in general population based on nine items (age, sex, body mass index, office BPs, Cornell index or Lewis index, QRS time, hs-TnT, and HbA1c). Additional clinical parameters improved sensitivity of Cornell index up to 86.0% (AUC:0.8011; 95% CI:0.748–0.854) from 64.9% (AUC:0.6450; 95% CI:0.573–0.716) in general population, to 92.9% (AUC:0.8423; 95% CI:0.760–0.924) from 64.3% (AUC:0.6481; 95% CI:0.518–0.779) in low CV risk patients, to 69.2% (AUC:0.6767; 95% CI:0.544–0.809) from 38.5% (AUC:0.5284; 95% CI:0.352–0.705) in moderate CV risk, and to 73.3% (AUC:0.7151
doi_str_mv 10.1093/ehjci/ehaa946.2918
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ehjci_ehaa946_2918</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ehjci/ehaa946.2918</oup_id><sourcerecordid>10.1093/ehjci/ehaa946.2918</sourcerecordid><originalsourceid>FETCH-LOGICAL-c818-bc83482dd7adad9bf25525df830577a41752db092005bde342efce89eedf2ff13</originalsourceid><addsrcrecordid>eNqNkEFOwzAQRS0EEqVwAVa-QIrtxIm9RFEpSJXYdMEucuxx4yqNLTutlNuT0h6Azczi_T8jPYReKVlRIvM36A7azVMpWZQrJqm4QwvKGctkWfB7tCBU8qwsxc8jekrpQAgRJS0XaKx7NzitenxW0am2h4TdMUR_BgzWzkRP2Fu8rjc4aR9nPHpsnNoPPgEeO8A92BGfYRij06deRdxNAeIYfegm7Aa8hwHi_CD4MOPR-eEZPVjVJ3i57SXafax39We2_d581e_bTAsqslaLvBDMmEoZZWRrGeeMGytywqtKFbTizLREMkJ4ayAvGFgNQgIYy6yl-RKx61kdfUoRbBOiO6o4NZQ0F23Nn7bmpq25aJtL2bXkT-E_-V9VSnWd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Clinical variables improve efficacy of ECG scores to diagnose the left ventricular hypertrophy in general population</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Jamiolkowski, J ; Chlabicz, M ; Paniczko, M ; Sowa, P ; Szpakowicz, M ; Lapinska, M ; Jurczuk, N ; Drobek, N.A ; Sawicka, E ; Raczkowski, A ; Kaminski, K.A</creator><creatorcontrib>Jamiolkowski, J ; Chlabicz, M ; Paniczko, M ; Sowa, P ; Szpakowicz, M ; Lapinska, M ; Jurczuk, N ; Drobek, N.A ; Sawicka, E ; Raczkowski, A ; Kaminski, K.A</creatorcontrib><description>Abstract   Left ventricular hypertrophy (LVH) is an important risk factor of various cardiovascular (CV) diseases and sudden death. Electrocardiography (ECG) is commonly used to detect LVH, but it has poor sensitivity, especially in high cardiovascular risk patients. Although echocardiography (ECHO) is a better, it is less available, and more expensive. Aim: To improve ECG scores to diagnose LVH in a general population. Methods The study was conducted in 2017–2019 in a representative sample of area residents. 717 volunteers randomly chosen from the local population were examined. Due to incomplete data, QRS complex duration ≥120ms, fascicular blocks, bundle branch blocks, paced rhythm, 216 people were excluded. Physical examination, ECG, ECHO and laboratory assessment were performed. In ECG LVH defined as &gt;28mm for men, &gt;20mm for women using Cornell index; &gt;17mm for both sexes using Lewis index. In ECHO LV mass was calculated using the Devereux Formula and indexed by body surface area (left ventricular mass index – LVMI). The LVH was defined as LVMI ≥115 g/m2 for man and ≥95 g/m2 for women. Cardiovascular risk was calculated based on the ESC SCORE and additional risk categories published in the latest ESC guidelines. We analyzed 4 models to predict the probability of LVH at ECHO: Model 1: Cornell index; Model 2: Lewis index; Model 3: Cornel index + clinical parameters (age, sex, BMI, office BPs, QRS time, hs-TnT, and HbA1c); Model 4: Lewis index + clinical parameters (age, sex, BMI, office BPs, QRS time, hs-TnT, and HbA1c). Associations between LVH and clinical and biochemical variables were earlier analyzed using multiple linear regression models, these parameters were independently associated with LVH. Results A total of 501 patients were included. The average age of patients was 49.0±15.35 years, and 203 probants (40.5%) were male. We developed a novel score to assess the probability of LVH at ECHO in general population based on nine items (age, sex, body mass index, office BPs, Cornell index or Lewis index, QRS time, hs-TnT, and HbA1c). Additional clinical parameters improved sensitivity of Cornell index up to 86.0% (AUC:0.8011; 95% CI:0.748–0.854) from 64.9% (AUC:0.6450; 95% CI:0.573–0.716) in general population, to 92.9% (AUC:0.8423; 95% CI:0.760–0.924) from 64.3% (AUC:0.6481; 95% CI:0.518–0.779) in low CV risk patients, to 69.2% (AUC:0.6767; 95% CI:0.544–0.809) from 38.5% (AUC:0.5284; 95% CI:0.352–0.705) in moderate CV risk, and to 73.3% (AUC:0.7151; 95% CI: 0.609–0.821) of Lewis index from 50.0% (AUC: 0.5630; 95% CI:0.448–0.678) in high and very-high CV risk class. Conclusions Addition of clinical parameters to ECG indices in the diagnosis of LVH markedly improves their diagnostic efficacy both in general population and in higher risk groups. The new score may be useful in guiding the appropriateness of ECHO study in general population, and especially in moderate and high CV risk patients, who are not always aware of the increased CV risk. ROC curves for recognize LVH. Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Medical University of Bialystok for Bialystok PLUS study</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/ehjci/ehaa946.2918</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2020-11, Vol.41 (Supplement_2)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com. 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Jamiolkowski, J</creatorcontrib><creatorcontrib>Chlabicz, M</creatorcontrib><creatorcontrib>Paniczko, M</creatorcontrib><creatorcontrib>Sowa, P</creatorcontrib><creatorcontrib>Szpakowicz, M</creatorcontrib><creatorcontrib>Lapinska, M</creatorcontrib><creatorcontrib>Jurczuk, N</creatorcontrib><creatorcontrib>Drobek, N.A</creatorcontrib><creatorcontrib>Sawicka, E</creatorcontrib><creatorcontrib>Raczkowski, A</creatorcontrib><creatorcontrib>Kaminski, K.A</creatorcontrib><title>Clinical variables improve efficacy of ECG scores to diagnose the left ventricular hypertrophy in general population</title><title>European heart journal</title><description>Abstract   Left ventricular hypertrophy (LVH) is an important risk factor of various cardiovascular (CV) diseases and sudden death. Electrocardiography (ECG) is commonly used to detect LVH, but it has poor sensitivity, especially in high cardiovascular risk patients. Although echocardiography (ECHO) is a better, it is less available, and more expensive. Aim: To improve ECG scores to diagnose LVH in a general population. Methods The study was conducted in 2017–2019 in a representative sample of area residents. 717 volunteers randomly chosen from the local population were examined. Due to incomplete data, QRS complex duration ≥120ms, fascicular blocks, bundle branch blocks, paced rhythm, 216 people were excluded. Physical examination, ECG, ECHO and laboratory assessment were performed. In ECG LVH defined as &gt;28mm for men, &gt;20mm for women using Cornell index; &gt;17mm for both sexes using Lewis index. In ECHO LV mass was calculated using the Devereux Formula and indexed by body surface area (left ventricular mass index – LVMI). The LVH was defined as LVMI ≥115 g/m2 for man and ≥95 g/m2 for women. Cardiovascular risk was calculated based on the ESC SCORE and additional risk categories published in the latest ESC guidelines. We analyzed 4 models to predict the probability of LVH at ECHO: Model 1: Cornell index; Model 2: Lewis index; Model 3: Cornel index + clinical parameters (age, sex, BMI, office BPs, QRS time, hs-TnT, and HbA1c); Model 4: Lewis index + clinical parameters (age, sex, BMI, office BPs, QRS time, hs-TnT, and HbA1c). Associations between LVH and clinical and biochemical variables were earlier analyzed using multiple linear regression models, these parameters were independently associated with LVH. Results A total of 501 patients were included. The average age of patients was 49.0±15.35 years, and 203 probants (40.5%) were male. We developed a novel score to assess the probability of LVH at ECHO in general population based on nine items (age, sex, body mass index, office BPs, Cornell index or Lewis index, QRS time, hs-TnT, and HbA1c). Additional clinical parameters improved sensitivity of Cornell index up to 86.0% (AUC:0.8011; 95% CI:0.748–0.854) from 64.9% (AUC:0.6450; 95% CI:0.573–0.716) in general population, to 92.9% (AUC:0.8423; 95% CI:0.760–0.924) from 64.3% (AUC:0.6481; 95% CI:0.518–0.779) in low CV risk patients, to 69.2% (AUC:0.6767; 95% CI:0.544–0.809) from 38.5% (AUC:0.5284; 95% CI:0.352–0.705) in moderate CV risk, and to 73.3% (AUC:0.7151; 95% CI: 0.609–0.821) of Lewis index from 50.0% (AUC: 0.5630; 95% CI:0.448–0.678) in high and very-high CV risk class. Conclusions Addition of clinical parameters to ECG indices in the diagnosis of LVH markedly improves their diagnostic efficacy both in general population and in higher risk groups. The new score may be useful in guiding the appropriateness of ECHO study in general population, and especially in moderate and high CV risk patients, who are not always aware of the increased CV risk. ROC curves for recognize LVH. Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Medical University of Bialystok for Bialystok PLUS study</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqNkEFOwzAQRS0EEqVwAVa-QIrtxIm9RFEpSJXYdMEucuxx4yqNLTutlNuT0h6Azczi_T8jPYReKVlRIvM36A7azVMpWZQrJqm4QwvKGctkWfB7tCBU8qwsxc8jekrpQAgRJS0XaKx7NzitenxW0am2h4TdMUR_BgzWzkRP2Fu8rjc4aR9nPHpsnNoPPgEeO8A92BGfYRij06deRdxNAeIYfegm7Aa8hwHi_CD4MOPR-eEZPVjVJ3i57SXafax39We2_d581e_bTAsqslaLvBDMmEoZZWRrGeeMGytywqtKFbTizLREMkJ4ayAvGFgNQgIYy6yl-RKx61kdfUoRbBOiO6o4NZQ0F23Nn7bmpq25aJtL2bXkT-E_-V9VSnWd</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Jamiolkowski, J</creator><creator>Chlabicz, M</creator><creator>Paniczko, M</creator><creator>Sowa, P</creator><creator>Szpakowicz, M</creator><creator>Lapinska, M</creator><creator>Jurczuk, N</creator><creator>Drobek, N.A</creator><creator>Sawicka, E</creator><creator>Raczkowski, A</creator><creator>Kaminski, K.A</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20201101</creationdate><title>Clinical variables improve efficacy of ECG scores to diagnose the left ventricular hypertrophy in general population</title><author>Jamiolkowski, J ; Chlabicz, M ; Paniczko, M ; Sowa, P ; Szpakowicz, M ; Lapinska, M ; Jurczuk, N ; Drobek, N.A ; Sawicka, E ; Raczkowski, A ; Kaminski, K.A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c818-bc83482dd7adad9bf25525df830577a41752db092005bde342efce89eedf2ff13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jamiolkowski, J</creatorcontrib><creatorcontrib>Chlabicz, M</creatorcontrib><creatorcontrib>Paniczko, M</creatorcontrib><creatorcontrib>Sowa, P</creatorcontrib><creatorcontrib>Szpakowicz, M</creatorcontrib><creatorcontrib>Lapinska, M</creatorcontrib><creatorcontrib>Jurczuk, N</creatorcontrib><creatorcontrib>Drobek, N.A</creatorcontrib><creatorcontrib>Sawicka, E</creatorcontrib><creatorcontrib>Raczkowski, A</creatorcontrib><creatorcontrib>Kaminski, K.A</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jamiolkowski, J</au><au>Chlabicz, M</au><au>Paniczko, M</au><au>Sowa, P</au><au>Szpakowicz, M</au><au>Lapinska, M</au><au>Jurczuk, N</au><au>Drobek, N.A</au><au>Sawicka, E</au><au>Raczkowski, A</au><au>Kaminski, K.A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical variables improve efficacy of ECG scores to diagnose the left ventricular hypertrophy in general population</atitle><jtitle>European heart journal</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>41</volume><issue>Supplement_2</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract   Left ventricular hypertrophy (LVH) is an important risk factor of various cardiovascular (CV) diseases and sudden death. Electrocardiography (ECG) is commonly used to detect LVH, but it has poor sensitivity, especially in high cardiovascular risk patients. Although echocardiography (ECHO) is a better, it is less available, and more expensive. Aim: To improve ECG scores to diagnose LVH in a general population. Methods The study was conducted in 2017–2019 in a representative sample of area residents. 717 volunteers randomly chosen from the local population were examined. Due to incomplete data, QRS complex duration ≥120ms, fascicular blocks, bundle branch blocks, paced rhythm, 216 people were excluded. Physical examination, ECG, ECHO and laboratory assessment were performed. In ECG LVH defined as &gt;28mm for men, &gt;20mm for women using Cornell index; &gt;17mm for both sexes using Lewis index. In ECHO LV mass was calculated using the Devereux Formula and indexed by body surface area (left ventricular mass index – LVMI). The LVH was defined as LVMI ≥115 g/m2 for man and ≥95 g/m2 for women. Cardiovascular risk was calculated based on the ESC SCORE and additional risk categories published in the latest ESC guidelines. We analyzed 4 models to predict the probability of LVH at ECHO: Model 1: Cornell index; Model 2: Lewis index; Model 3: Cornel index + clinical parameters (age, sex, BMI, office BPs, QRS time, hs-TnT, and HbA1c); Model 4: Lewis index + clinical parameters (age, sex, BMI, office BPs, QRS time, hs-TnT, and HbA1c). Associations between LVH and clinical and biochemical variables were earlier analyzed using multiple linear regression models, these parameters were independently associated with LVH. Results A total of 501 patients were included. The average age of patients was 49.0±15.35 years, and 203 probants (40.5%) were male. We developed a novel score to assess the probability of LVH at ECHO in general population based on nine items (age, sex, body mass index, office BPs, Cornell index or Lewis index, QRS time, hs-TnT, and HbA1c). Additional clinical parameters improved sensitivity of Cornell index up to 86.0% (AUC:0.8011; 95% CI:0.748–0.854) from 64.9% (AUC:0.6450; 95% CI:0.573–0.716) in general population, to 92.9% (AUC:0.8423; 95% CI:0.760–0.924) from 64.3% (AUC:0.6481; 95% CI:0.518–0.779) in low CV risk patients, to 69.2% (AUC:0.6767; 95% CI:0.544–0.809) from 38.5% (AUC:0.5284; 95% CI:0.352–0.705) in moderate CV risk, and to 73.3% (AUC:0.7151; 95% CI: 0.609–0.821) of Lewis index from 50.0% (AUC: 0.5630; 95% CI:0.448–0.678) in high and very-high CV risk class. Conclusions Addition of clinical parameters to ECG indices in the diagnosis of LVH markedly improves their diagnostic efficacy both in general population and in higher risk groups. The new score may be useful in guiding the appropriateness of ECHO study in general population, and especially in moderate and high CV risk patients, who are not always aware of the increased CV risk. ROC curves for recognize LVH. Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Medical University of Bialystok for Bialystok PLUS study</abstract><pub>Oxford University Press</pub><doi>10.1093/ehjci/ehaa946.2918</doi></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2020-11, Vol.41 (Supplement_2)
issn 0195-668X
1522-9645
language eng
recordid cdi_crossref_primary_10_1093_ehjci_ehaa946_2918
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Clinical variables improve efficacy of ECG scores to diagnose the left ventricular hypertrophy in general population
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T22%3A43%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20variables%20improve%20efficacy%20of%20ECG%20scores%20to%20diagnose%20the%20left%20ventricular%20hypertrophy%20in%20general%20population&rft.jtitle=European%20heart%20journal&rft.au=Jamiolkowski,%20J&rft.date=2020-11-01&rft.volume=41&rft.issue=Supplement_2&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/ehjci/ehaa946.2918&rft_dat=%3Coup_cross%3E10.1093/ehjci/ehaa946.2918%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ehjci/ehaa946.2918&rfr_iscdi=true